Cedar Clinical Research to Host Phase III Trial for Investigational Therapy for SchizophreniaTORONTO, ON / ACCESSWIRE / September 13, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychede...Read More
TORONTO, ON / ACCESSWIRE / September 9, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that, effective today, its common shares have been approv...Read More
TORONTO, ON / ACCESSWIRE / September 8, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce its participation in the H.C. Wainwright 23rd Annual G...Read More
TORONTO, ON / ACCESSWIRE / August 11, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced that it has completed the sale of the Company's investment in t...Read More
Samantha DeLenardo joins from CAMH, Canada's largest mental health teaching hospital and leader in mental health researchTORONTO, ON / ACCESSWIRE / August 6, 2021 / Novamind Inc., (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), leading mental health compa...Read More
Company executes organic growth mandate, on track to open four new clinics by Q3 2021TORONTO, ON / ACCESSWIRE / July 29, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medici...Read More
Aims to increase visibility and facilitate investment for United States investorsTORONTO, ON / ACCESSWIRE / July 21, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine,...Read More
Cedar Clinical Research to Host Phase IIb Trial for a Novel PTSD TreatmentTORONTO, ON / ACCESSWIRE / July 8, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleas...Read More
Aimed at an audience of psychedelic medicine researchers and cliniciansTORONTO, ON / ACCESSWIRE / June 30, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today anno...Read More
Led first-of-its-kind study of group psilocybin therapy for cancer patients with depressionCo-Investigator on a study to evaluate ketamine as a treatment for opioid use disorderWill lead Novamind's clinical research arm focused on psychedelic medicineTORONTO, ON / ACCESSWIRE / June 23, 2021...Read More
TORONTO, ON / ACCESSWIRE / June 17, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, announces that it has made a strategic investment of US$1,000,000 (the "Stra...Read More
Novamind to be featured in panel discussions on the disruptive potential of psychedelic treatmentsTORONTO, ON / ACCESSWIRE / June 15, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psych...Read More
Novamind and the Wholeness Center to launch clinical offering in Utah and ColoradoTORONTO, ON / ACCESSWIRE / June 10, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine,...Read More
Revenue of $1,846,132 for Fiscal Q3 2021, +43% quarter-over-quarterAnnounced doubling of clinic network by September 2021Forecasting 65,000 clinic visits in 2021, +225% year-over-yearTORONTO, ON / ACCESSWIRE / June 1, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind&quo...Read More
MONTREAL, June 01, 2021 (GLOBE NEWSWIRE) -- Nemaska Lithium Inc. (“Nemaska Lithium” or “Company”) announces that it has entered into an option agreement to purchase a 500,000m² plot of land in the Industrial park and port of Bécancour (“Béc...Read More
Invests in care support systems to facilitate rapid expansionTORONTO, ON / ACCESSWIRE / May 18, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, has opened a new Nova...Read More
New clinics represent the first phase of Novamind's national expansion strategyTORONTO, ON / ACCESSWIRE / May 4, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine,...Read More
Novamind working with Center for Change to treat patients, conduct researchTORONTO, ON / ACCESSWIRE / April 21, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, has s...Read More
TORONTO, ON / ACCESSWIRE / April 20, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, will present at the SNN Planet MicroCap Showcase on Thursday, April 22nd at 10:0...Read More
TORONTO, ON / ACCESSWIRE / April 19, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, will present at the SNN Planet MicroCap Showcase on Thursday, April 22nd at 10:0...Read More